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Abstract 
Purpose: To investigate the inhibitory effect of berberine treatment on enhancement of zeste of 
homolog 2 (Ezh2) expressions in KYSE450 human esophageal cancer cells.   
Methods: Transwell motility chambers were used to analyze cell migration and invasion. Bio-Rad 
protein assay was used for the determination of protein concentration. Chemiluminescence with ECL 
system was employed for the detection of protein bands as per the manufacturer’s protocol. Staining 
was carried out with Alexa-Fluor 647 mouse anti-BrdU antibody. Flow cytometry was performed after 
adding DAPI. Annexin-V/DAPI staining and flow cytometry were used for the quantification of apoptotic 
cell death. Total RNA was isolated from KYSE450 cells using an RNA isolation kit. 
Results: Berberine-induced inhibition of Ezh2 expression led to inhibition of cell proliferation by G1 
phase cell cycle arrest and induced anti-invasive properties of KYSE450 cells in Boyden chamber 
assays. There was 92 % reduction in invasive tendency of KYSE450 cells following treatment with 
berberine. Histone methylation inhibitor, 3-deazaneoplanocin A (DZNep), also led to a similar effect on 
cell proliferation of KYSE450 cells. Berberine treatment also resulted in strong transcriptional reduction 
of the AXL receptor kinase. The results of qRT-PCR and FACS analyses showed significant inhibition of 
AXL mRNA and protein expression in KYSE450 carcinoma cells after treatment with berberine.  
Conclusion: Berberine may be an effective therapeutic agent in the treatment of esophageal 
carcinoma. 
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During embryonic development cell fate decision 
is mainly regulated by polycomb group (PcG) 
proteins [1-3]. The two multi-protein complexes 
namely polycomb repressive complexes 1 and 2 
(PRC1 and PRC2) are involved in repression of 
transcription. PRC2 comprises Ezh2 (enhancer 
of Zeste homolog 2), Suz12 (suppressor of Zeste 
12), and EED (embryonic ectoderm 
development) [3]. The lysine methyl transfer and 
trimethylation of histone 3 at lysine 27 
(H3K27me3) is performed by Ezh2 and Ezh2-
containing PRC2 respectively [4]. Several 
genome-wide integrative studies have revealed 
crucial roles of the polycomb pathway in cancer 
initiation and progression [5-7]. Ezh2 is highly 
expressed and its expression positively 
correlates with tumor malignancy and 
invasiveness in many cancers [8-10]. Based on 
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this background, we investigated the histone 
methylation-independent role of EZH2 in GSC 
self-renewal and GBM propagation. 
 
Berberine, an isoquinoline alkaloid of 
protoberberine class [11] inhibits cell growth in 
several types of human cancers [12-14]. It is 
reported to inhibit growth of cancer cells by 
inhibiting DNA topoisomerase I, inducing cell-
cycle arrest and apoptosis through Fas/FasL 
signalling pathways and activation of caspase-3 
[15]. There are reports that berberine can 
suppress the invasive properties of 
nasopharyngeal carcinoma cell lines through 
inhibiting the activities of Rho GTPases [16]. 
Berberine can suppress metastasis by enhancing 
the expression of a metastasis suppression 
gene, NM23-H1, or by targeting Rho kinase-
mediated ezrin phosphorylation in NPC 5-8 F cell 
line [15,17]. It also enhances the anti-cancer 
effects of estrogen receptor antagonists on 
human breast cancer cells (MCF-7) through 
down-regulating the expression of EGFR, HER2, 
Bcl-2, and COX-2, as well as upregulating IFN-α 
and p21 [18]. With this wide spectrum of anti-
tumor properties, berberine has potential 
application as a complementary medicine for 





Cell culture and reagents 
 
Human esophageal cancer KYSE450 cells were 
purchased from the Health Science Research 
Resources Bank (Osaka, Japan). The cells were 
maintained in Dulbecco's Modified Eagle's 
Medium (DMEM; Invitrogen) with 10 % FBS. 
Berberine, 5-aza-29-deoxycytidine (5-aza) and 
suberoylanilide hydroxamic acid (SAHA) were 
purchased from Sigma (St. Louis, MO, USA). 
Trichostatin A (TSA) was obtained from Cayman 
chemicals (Hamburg, Germany). Stock solutions 
of 5-aza, SAHA and TSA were prepared in 
dimethyl sulfoxide (DMSO) and that of DZNep in 
water.  
 
Migration and invasion assay 
 
Transwell motility chambers were used to 
analyse cell migration and invasion. For this, 8-
mm pore diameter transwell motility chambers 
(Corning) were coated with matrigel (BD 
Biosciences) on undesurface. Into the upper 
chamber, 2 × 106 cells were plated in serum-free 
culture medium and the lower chamber was filled 
with medium containing 10 % FBS. The plates 
were incubated for 24 h at 37 oC. After incubation 
the upper surface of the compartment was 
cleaned. The inserts after methanol fixing were 
stained with crystal violet solution (0.5 %) 
followed by microscopic examination. The 5 
areas were randomly selected and the cells were 
calculated. Experiments were performed in 
triplicates. 
 
Western blot analysis 
 
KYSE450 cells were treated with an ice cold 
solution of tris(hydroxymethyl) aminomethane 
hydrochloride (Carl Roth) containing 150 µM 
NaCl, 1 % Nondiet P-40 (Genaxxon Bioscience, 
Ulm, Germany), 10 µM ethylenediamine-
tetraacetic acid (EDTA) (GerbuBiotechnik, 
Gaiberg, Germany), 200 µM dithiothreitol (Carl 
Roth), 100 µM phenylmethylsulphonyl fluoride 
(PMSF) and complete EDTA-free (1:50, Roche, 
Mannheim Germany) for 30 min. After lysis, the 
lysate was centrifuged for 20 min (12000 rpm) to 
remove the non-dissolved matter. Bio-Rad 
protein assay (Bio-Rad, Hercules, CA, USA) was 
used for estimation of protein concentration. 
Proteins were separated on SDS-PAGE and 
transferred to polyvinylidene difluoride (PVDF) 
membranes (Amersham Bioscience) blocked 
with milk. The membranes were then probed with 
antibodies. Chemiluminescence with the ECL 
system (Vigorous) was used for detection of 
protein bands as per the manufactures protocol. 
 
Cell cycle analysis 
 
Cells were incubated with 10 µM 
bromodeoxyuridine (BrdU, BD Bioscience, 
Heidelberg, Germany) for 1 h.  After incubation 
the cells were harvested, fixed in ice-cold 
methanol and treated with a PBS-based buffer 
containing 0.1 M hydrochloric acid (VWR) and 
0.3 % Triton X-100 for 20 min at 4 oC. The cells 
were then boiled in water to expose the DNA. 
Staining was performed for 30 min with Alexa-
Fluor 647 mouse anti-BrdU antibody (clone 3D4, 
1:50, BD Bioscience). Prior to flow cytometry 
using a BD FACS CANTO II cytometer (BD 





We used annexin-V/DAPI staining and flow 
cytometry for quantification of apoptotic cell 
death. For DZNep toxicity, cells were treated with 
DZNep for 120 h, washed with PBS followed by 
treatment with Annexin-V-FITC and DAPI 
containing Annexin-binding buffer. Cells were 
then incubated for 10 min followed by flow 
cytometry examination using a BD FACS 
CANTO II cytometer. For AXL surface 
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expression cells after incubation were harvested 
with accutase treatment (PAA), washed with PBS 
containing 3 % FBS and 2 µM EDTA. Again the 
cells were incubated with polyclonal goat anti-
AXL or polyclonal goat IgG on ice and then 
stained with secondary Alexa Fluor 488 goat 
anti-goat antibody (1:200, Invitrogen) for 30 min. 
 
Quantitative real-time PCR 
 
Total RNA was isolated from KYSE450 cells 
using the Qiagen RNAeasy RNA isolation kit 
(Hilden, Germany). Using Applied Biosystems 
reverse-transcription-Kit (Foster City, CA, USA) 
one mg RNA was subjected to reverse 
transcription and ABI 7000 thermal cycler with 
SYBR Green PCR Mastermix (Applied 
Biosystems, Carlsbad, USA) was used for QRT-
PCR. For relative quantification of gene 
expression threshold values were compared and 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as housekeeping gene. All 
samples were analysed in triplicate and the 





We used Student t test with the SPSS13.0 
statistical program for windows comparing EZH2 
expression. The other data were expressed as 
the mean ± SD. A value of p less than 0.05 was 




Ezh2 expression in human esophageal 
cancer cell lines 
 
We observed a significant Ezh2 expression in 
esophageal carcinoma cells KYSE450, TE-1, 
KY-5, KY-10, YES-1 and YES-2 compared to 
that in normal cells (Fig. 1A). The results 
revealed a strong correlation between intensity of 
staining and the extent of malignancy (Fig. 1B). 
Compared to invasion front, the expression of 
Ezh2 was stronger in perinecrotic areas (Fig. 
1C). These results demonstrate that expression 





Fig 1: Ezh2 expression in human esophageal cancer cell lines. (A) Western blot showing Ezh2 expression in 
indicated cell lines using tubulin as loading control. (B) Ezh2 expression in KYSE450 cells. (C) Ezh2 expression 
in KYSE450 cells in necrotic regions 
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Effect of berberine on Ezh2 expression, 
proliferation inhibition and invasion of 
carcinoma cell migration 
 
Treatment of KYSE450 esophageal cancer cells 
with berberine led to inhibition of Ezh2 
expression and the effect continued for 2 days 
(Fig 2A). Berberine treatment also inhibited cell 
proliferation by inducing a G1 phase cell cycle 
arrest (Fig 2B). Berberine-induced knockdown of 
Ezh2 resulted in anti-invasive properties of 
carcinoma cells in Boyden chamber assays. 
There was 92 % reduction in invasive tendency 
of KYSE450 cells on treatment with berberine 
(Fig. 2C). For confirmation of Ezh2 inhibition by 
berberine treatment, the KYSE450 cells were 
treated with histone methylation inhibitor 3-
deazaneoplanocin A (DZNep). Although there 
was no toxic effect of DZNep treatment at 5 µM 
concentration cell proliferation was inhibited to 
the same extent as after berberine treatment 
(Fig. 2D).  
 
Treatment of KYSE450 carcinoma cells with 
berberine as well as with 5 µM DZNep resulted in 
significant reduction of H3K27 trimethylation (Fig 
2E). However unlike berberine, treatment with 
DZNep did not result in inhibition of invasiveness 






Fig 2: Effect of berberine on Ezh2 expression. (A) Western blot showing berberine treatment decreases Ezh2 
expression after 24 hours using tubulin as loading control. (B) Cell cycle analysis of KYSE450 cells after 2 days 
of berberine treatment. (C) Migration of KYSE450 cells after berberine treatment through a matrigel-coated 
Boyden chamber. (D) Effect of DZNep (5 µM) on H3K27me3 methylation. (E) Effect of DZNep (5 µM) on 
H3K27me3 methylation or after berberine-induced Ezh2 inhibition. (F) Matrigel boyden chamber assay of 
KYSE450 cells 
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Fig 3: (A) AXL protein expression in the human KYSE450 carcinoma cells after treatment with berberine. (B) 
Analysis of protein expression in KYSE450 carcinoma cells after treatment with berberine 
 
Transcriptional profiling of Ezh2-knockdown 
in human malignant cancer cells 
 
We observed significant inhibition of the gene 
receptor tyrosine kinase AXL in KYSE450 
carcinoma cells after berberine treatment (Fig 
3A). The results from qRT-PCR and FACS 
analyses showed significant inhibition of AXL 
mRNA and protein expression in KYSE450 





The gene receptor tyrosine kinase AXL has been 
shown to be involved in tumor invasiveness and 
metastases in multiple tumors [20-24]. There are 
reports that berberine can suppress the invasive 
properties [25] and suppress metastasis by 
enhancing the expression of a metastasis 
suppression gene, NM23-H1, or by targeting Rho 
kinase-mediated ezrin phosphorylation in NPC 5-
8 F cell line [22,26]. We observed a significant 
inhibition of AXL mRNA and protein expression 
in KYSE450 carcinoma cells after treatment with 
berberine. Ezh2 is believed to regulate cell 
motility through AXL transactivation in cancer 
cells as well as in stem cells during development. 
In KYSE450 carcinoma cells which are known to 
possess migration tendency we observed a 
strong Ezh2 expression in perinecrotic areas. 
Berberine treatment led to suppression of Ezh2 
expression and inhibition of cell proliferation by 
inducing a G1 phases cell cycle arrest. Berberine 
induced suppression of Ezh2 also resulted anti-
invasive properties of KYSE450 carcinoma cells. 
Berberine treatment led to inhibition of the stem 
cell marker nestin which correlates with earlier 
reports [13] depicting the key role of Ezh2 for 
maintaining a stem cell phenotype in malignant 
cancers.  
 
Recent studies indicate that DZNep globally 
suppresses histone methylation [27]. Inhibition of 
histone trimethylation by DZNep not only 
depletes Ezh2 by inducing its proteasomal 
degradation but also other proteins of the PRC2 
complex [26,28,29]. The results from our study 
demonstrate that Ezh2 activates transcription of 
AXL mRNA in a methylation-independent 
manner. Treatment of KYSE450 carcinoma cells 
with DZNep did not affect AXL expression. It is 
possible that other components of the PRC2 
such as SUZ12 or EED silence AXL mRNA 
expression while Ezh2 positively regulates AXL.  
While we initially postulated that HDAC are 
directly involved in mediating modulation of AXL 
transcription by EZH2 in gliomas, our data 
suggest that inhibition of HDAC suppress AXL 
transcription by transcriptional control of Ezh2, 
indicating that Ezh2 is under transcriptional 
control of HDAC also in KYSE450 carcinoma 
cells. Although the exact molecular mechanisms 
driving AXL gene expression through EZH2 
remain elusive, the identification of AXL as a 
novel target of Ezh2 adds further evidence to the 
molecular network influenced by Ezh2 to sustain 




The findings of this study demonstrate that 
berberine-induced inhibition of Ezh2 expression 
leads to inhibition of cell proliferation by G1 
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phase cell cycle arrest and induces anti-invasive 
properties of KYSE450 cells in Boyden chamber 
assays. Thus, berberine may be an effective 
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